We compared the effects of acyclovir (ACV) and 9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG) on murine cytomegalovirus (MCMV) replication in lung and salivary gland tissues, the evolution of interstitial pneumonitis in vivo, and MCMV replication in mouse embryo cells in vitro. As measured by plaque reduction, ACV was more active than DHPG in vitro. In vivo, whether administered orally by gastric intubation or in the drinking water, or subcutaneously, DHPG was more effective than ACV in reducing MCMV titers in lung or salivary gland tissues. This was true in both normal and cyclophosphamide-treated mice. Neither drug was able to prevent MCMV interstitial pneumonitis, despite substantial reductions in virus titer, but both drugs reduced the severity of the pneumonitis.Lung infection and interstitial pneumonitis due to cytomegalovirus (CMV) constitute common and often lifethreatening problems for individuals whose immune defenses have been altered by disease or medical therapy (3). The pathogenetic mechanisms leading to CMV lung infection and interstitial pneumonitis are poorly understood. However, the advent of successful antiviral chemotherapy for other herpesvirus infections has prompted a search for therapeutic modalities which might improve the prospects of individuals with pulmonary involvement due to CMV. At present, the available shemotherapeutic agents have poor in vitro antiviral activity against most strains of CMV, and uncontrolled therapeutic trials of agents such as interferon, acyclovir (ACV), and vidarabine against CMV interstitial pneumonitis have been disappointing (4,5,10,11). The search for more effective antiviral agents for the treatment of CMV interstitial pneumonitis is an area of intense interest.We have been studying a model of murine CMV (MCMV) lung infection to better define the roles of host and viral factors in the genesis of MCMV interstitial pneumonitis (8, 9). In BALB/c mice inoculated intranasally with MCMV,